The Curative Effect Evaluation and Daily Monitoring of TCM Constitution Diet Control and Physical Training in the Prevention and Treatment of Simple Fatty Liver

注册号:

Registration number:

ITMCTR2000003804

最近更新日期:

Date of Last Refreshed on:

2020-08-28

注册时间:

Date of Registration:

2020-08-28

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

基于中医体质学说的饮食控制联合运动干预防治单纯性脂肪肝的疗效评价和日常监测研究

Public title:

The Curative Effect Evaluation and Daily Monitoring of TCM Constitution Diet Control and Physical Training in the Prevention and Treatment of Simple Fatty Liver

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于中医体质学说的饮食控制联合运动干预防治单纯性脂肪肝的疗效评价和日常监测研究

Scientific title:

The Curative Effect Evaluation and Daily Monitoring of TCM Constitution Diet Control and Physical Training in the Prevention and Treatment of Simple Fatty Liver

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000037395 ; ChiMCTR2000003804

申请注册联系人:

周振华

研究负责人:

周振华

Applicant:

Zhen-Hua Zhou

Study leader:

Zhen-Hua Zhou

申请注册联系人电话:

Applicant telephone:

+86 21-20256011

研究负责人电话:

Study leader's telephone:

+86 21-20256011

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jinghua1220@163.com

研究负责人电子邮件:

Study leader's E-mail:

jinghua1220@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市浦东新区张衡路528号

研究负责人通讯地址:

上海市浦东新区张衡路528号

Applicant address:

528 Zhangheng Road, Pudong District, Shanghai, China

Study leader's address:

528 Zhangheng Road, Pudong District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海中医药大学附属曙光医院

Applicant's institution:

Shuguang Hospital Affiliated Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2020-sgys-074

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

上海中医药大学附属曙光医院伦理委员会

Name of the ethic committee:

Ethic Committee of Shuguang Hospital Affiliated Shanghai University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/8/24 0:00:00

伦理委员会联系人:

耿希

Contact Name of the ethic committee:

Xi Geng

伦理委员会联系地址:

上海市浦东新区张衡路528号

Contact Address of the ethic committee:

528 Zhangheng Road, Pudong District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海中医药大学附属曙光医院

Primary sponsor:

Shuguang Hospital Affiliated Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市浦东新区张衡路528号

Primary sponsor's address:

528 Zhangheng Road, Pudong District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海申康医院发展中心

具体地址:

康定路 2 号

Institution
hospital:

Shanghai Shen Kang Hospital Development Center

Address:

2 Kangding Road

经费或物资来源:

促进市级医院临床技能与临床创新三年行动计划

Source(s) of funding:

Three year plan of action for promoting clinical skills and clinical innovation in municipal hospitals

研究疾病:

非酒精性脂肪性肝病

研究疾病代码:

Target disease:

Non-alcoholic fatty liver disease

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

评价基于中医体质学说的饮食控制联合运动干预方案防治单纯性脂肪肝的临床疗效和安全性。

Objectives of Study:

Objective to evaluate the clinical efficacy and safety of diet control combined with exercise intervention program in the prevention and treatment of simple fatty liver.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

① 符合单纯性脂肪肝的临床诊断标准和影像学诊断标准; ② 符合单纯性脂肪肝的中医病名诊断标准和体质诊断标准; ③ 年龄18~65周岁,性别不限; ④ 体质量(BMI)≥28且腰围身高比值(WHtR)>0.5即腹型肥胖患者 ⑤ 同意接受中医药、饮食和运动干预,签订知情同意书的患者。

Inclusion criteria

1. The clinical and imaging diagnostic criteria of simple fatty liver were met; 2. According to the diagnostic criteria of TCM disease name and constitution of simple fatty liver; 3. The age ranged from 18 to 65 years old; 4. Patients with body mass (BMI) >= 28 and WHtR > 0.5 were defined as abdominal obesity; 5. Patients who agree to accept traditional Chinese medicine, diet and exercise intervention and sign informed consent.

排除标准:

① 合并由病毒性肝炎、药物中毒、免疫性疾病等因素所致的肝炎、血吸虫肝病或肝硬化患者; ② 伴有心、肾、肺、内分泌、血液、代谢及胃肠道严重原发病者; ③ 对研究方案依从性差的受试者或近期或正在参加其他临床试验者; ④ 哺乳、妊娠或正准备妊娠的妇女。

Exclusion criteria:

1. Patients with hepatitis, schistosomiasis liver disease or liver cirrhosis caused by viral hepatitis, drug poisoning, immune diseases, etc; 2. Patients with severe primary diseases of heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract; 3. Subjects with poor adherence to the study protocol or those who have recently or are participating in other clinical trials; 4. A woman who is breastfeeding, pregnant, or preparing for pregnancy.

研究实施时间:

Study execute time:

From 2020-10-01

To      2022-09-30

征募观察对象时间:

Recruiting time:

From 2020-12-01

To      2021-12-31

干预措施:

Interventions:

组别:

治疗组

样本量:

116

Group:

treatment group

Sample size:

干预措施:

中医体质饮食控制

干预措施代码:

Intervention:

constitution of TCM diet control

Intervention code:

组别:

对照组

样本量:

116

Group:

control group

Sample size:

干预措施:

地中海饮食控制

干预措施代码:

Intervention:

mediterranean diet control

Intervention code:

组别:

治疗组

样本量:

116

Group:

treatment group

Sample size:

干预措施:

运动干预

干预措施代码:

Intervention:

physical training

Intervention code:

组别:

对照组

样本量:

116

Group:

control group

Sample size:

干预措施:

运动干预

干预措施代码:

Intervention:

physical training

Intervention code:

样本总量 Total sample size : 232

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属曙光医院

单位级别:

三级甲等

Institution/hospital:

Shu Guang Hospital Affiliated Shanghai University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

胰岛素

指标类型:

次要指标

Outcome:

insulin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能

指标类型:

副作用指标

Outcome:

renal function

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝脏脂肪定量

指标类型:

主要指标

Outcome:

MRI-PDFF

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心电图

指标类型:

副作用指标

Outcome:

electrocardiogram

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体质量

指标类型:

主要指标

Outcome:

Body Mass Index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血脂水平

指标类型:

次要指标

Outcome:

lipid levels

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

次要指标

Outcome:

liver function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

副作用指标

Outcome:

routine blood test

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血糖水平

指标类型:

次要指标

Outcome:

blood glucose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候量表

指标类型:

次要指标

Outcome:

TCM Syndrome Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

根据样本量,由统计人员应用SAS统计软件产生随机数字表,每4例患者为1个随机block。

Randomization Procedure (please state who generates the random number sequence and by what method):

According to the sample size, using of statistical software SAS statistical software generated a random digital table by the statistical researcher , every four patients is one random block.

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

本研究在2023年3月31日后应用“医数据”网络数据平台共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Using the web-bassed public database of

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

应用“医数据”网络数据平台保存和管理原始数据,原始病例记录保存于上海中医药大学附属曙光医院档案室。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Using the web-bassed public database of "www.ydate.org" to management of the metadata,and the original case report from were preserved in the archives of Shu Guang Hospital Affiliated Shanghai University of Traditional Chinese Medicine

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above